Singapore markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
61.53+0.44 (+0.72%)
As of 10:48AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close61.09
Open61.00
Bid61.46 x 1400
Ask61.46 x 1000
Day's range60.82 - 61.61
52-week range57.17 - 74.12
Volume1,377,889
Avg. volume7,223,551
Market cap77.178B
Beta (5Y monthly)0.35
PE ratio (TTM)18.82
EPS (TTM)3.27
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yield2.92 (4.78%)
Ex-dividend date14 Sept 2022
1y target est69.96
  • Motley Fool

    2 Reasons This Beaten-Down Stock Could Be About to Rebound

    Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.

  • Business Wire

    Gilead Sciences to Acquire MiroBio

    FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.